London, UK – [Date of Publication] – In a significant advance for cancer research, an international consortium of scientists has unveiled a previously unrecognized link between the natural process of ageing and the progression of cancerous tumours. Researchers from the Francis Crick Institute, UCL, Gustave Roussy, and Memorial Sloan Kettering Cancer Center (MSK) have discovered that the expansion of mutant blood cells, a phenomenon commonly associated with ageing, can infiltrate cancerous tumours, a condition they term Tumour Infiltrating Clonal Haematopoiesis (TI-CH). This infiltration is not merely an incidental finding; it is directly associated with significantly worse outcomes for patients across a spectrum of cancer types.
Published today in the prestigious New England Journal of Medicine, this comprehensive study fundamentally reshapes our understanding of the tumour microenvironment and the systemic factors that influence cancer evolution. The findings highlight the critical interplay between age-related genetic changes and the development of aggressive cancers, opening new avenues for both prognostic assessment and therapeutic intervention. This work underscores the urgent need to understand the biological interface of age-related genetic changes and diseases of ageing, such as cancer and cardiovascular disease, to develop more effective preventative and treatment strategies for an increasingly ageing global population.
Main Facts: A Hidden Threat from Ageing Blood
The core discovery centres on "Clonal Haematopoiesis of Indeterminate Potential" (CHIP), a condition where blood stem cells accumulate specific mutations over time. Influenced by both chronological ageing and environmental factors, CHIP has long been recognized for its association with an elevated risk of age-related disorders, notably cardiovascular disease. However, its direct impact on the progression and prognosis of solid cancers remained largely uninvestigated until now.
This landmark research reveals that when these CHIP-mutated blood cells infiltrate solid tumours, they form TI-CH, which is a potent predictor of poorer patient prognosis. The study, involving an initial cohort of over 400 lung cancer patients from the Cancer Research UK-funded TRACERx and PEACE studies, and subsequently validated in a massive dataset of 49,000 patients with diverse cancer types from MSK, demonstrated that patients with TI-CH faced a shorter survival period, irrespective of their age or the stage at which their cancer was diagnosed.
Crucially, the researchers identified that it was the presence of these mutant blood cells within the tumour itself – TI-CH – rather than just in the bloodstream (CHIP alone), that significantly correlated with an increased risk of cancer relapse and mortality. Further mechanistic investigations pinpointed a specific gene, TET2, as a key player. Mutations in TET2 were found to drive the infiltration of myeloid cells – a type of immune cell known to regulate inflammation and support tumour growth – into the tumour microenvironment, thereby accelerating tumour progression. This discovery sheds new light on how systemic age-related changes can actively contribute to the aggressiveness of cancer, offering a fresh perspective on a disease often viewed primarily through the lens of mutations within the cancer cells themselves.
Chronology: Tracing the Interplay of Ageing and Cancer
The journey to this groundbreaking discovery began with a recognized gap in scientific understanding. While the existence of CHIP and its links to cardiovascular disease were established, its role in the complex ecosystem of solid tumours was largely uncharted territory. Researchers hypothesized that if age-related genetic changes in blood cells could influence systemic inflammation and other age-related diseases, they might also play a part in the intricate dynamics of cancer.
The initial phase of the investigation leveraged existing, comprehensive cancer research initiatives. The Cancer Research UK-funded TRACERx (Tracking Cancer Evolution through therapy (Rx)) study, known for its meticulous genomic analysis of lung cancer evolution, provided an invaluable cohort of over 400 lung cancer patients. Alongside this, the PEACE (Post-mortem Examination of Advanced Cancer Environments) study, which offers unparalleled insights into metastatic sites – the primary cause of cancer death – provided crucial post-mortem tissue samples.
The first step involved a meticulous examination of blood samples from these lung cancer patients to identify the presence of CHIP mutations. Once identified, this data was correlated with extensive clinical records. The initial observation was stark: patients with CHIP mutations in their blood exhibited a statistically significant association with shorter overall survival. This finding prompted a deeper dive, leading the team to question whether these mutations were merely circulating or actively participating in the tumour’s environment.
This led to the critical distinction of Tumour Infiltrating Clonal Haematopoiesis (TI-CH). The researchers then painstakingly analyzed tumour biopsies, confirming that in a substantial proportion (42%) of CHIP patients, these specific mutations were indeed present within the lung tumours, having infiltrated the cancerous tissue. The subsequent analysis unequivocally demonstrated that it was TI-CH, and not CHIP alone, that was the true harbinger of a worse prognosis, strongly correlating with increased cancer relapse and death. The PEACE study data further solidified this, revealing the frequent presence of TI-CH mutations in metastatic tumours, underscoring their potential role in cancer dissemination.
The scientific inquiry then shifted to the ‘how.’ To unravel the mechanisms behind TI-CH’s detrimental effects, the team delved into the cellular composition of the tumour microenvironment. This led to the identification of an expansion of myeloid cells, a specific type of immune cell, within the tumours of TI-CH patients. Recognizing the dual nature of myeloid cells – some immune cells fight cancer, others can promote it – the researchers focused on their pro-tumour functions.
Further genetic analysis across thousands of individuals highlighted the TET2 gene as a critical factor. Mutations in TET2, known for its role in regulating blood cell production, were found to be particularly prone to infiltrating tumours. Single-cell sequencing of tumour samples from TI-CH patients confirmed that TET2 mutations were predominantly located within these myeloid cells, rather than other immune cell types.
To provide robust experimental validation, the team collaborated with blood cancer and CHIP experts at the Crick, led by Dominique Bonnet. Through innovative organoid models – mini lung tumours grown in vitro – they demonstrated that TET2 mutant myeloid cells actively remodelled the tumour microenvironment and dramatically accelerated tumour organoid growth, providing direct evidence of their pro-tumourigenic activity.
The final, and perhaps most impactful, chronological step involved a large-scale validation. Collaborating with Memorial Sloan Kettering Cancer Center, the team extended their analysis to an unprecedented dataset of over 49,000 patients with a wide array of cancer types. This massive validation confirmed the initial findings: the presence of TI-CH consistently emerged as an independent predictor of shorter survival across various malignancies, solidifying its clinical relevance and universal applicability. This meticulous, multi-stage research effort, from initial observation to mechanistic validation and broad-scale confirmation, exemplifies the rigorous process of scientific discovery.
Supporting Data: Deciphering the Mechanisms of Tumour Infiltration
The study’s strength lies in its comprehensive data, which not only identifies a critical association but also begins to unravel the underlying biological mechanisms.
The Enigma of Clonal Haematopoiesis (CHIP)
Clonal haematopoiesis of indeterminate potential (CHIP) is a silent, age-related phenomenon affecting a significant portion of the elderly population. It arises when a single haematopoietic stem cell in the bone marrow acquires a somatic mutation and subsequently expands, creating a "clone" of genetically identical blood cells. These mutations are not inherently cancerous but confer a survival advantage to the mutated stem cell, leading to its disproportionate proliferation. Common driver genes for CHIP include TET2, DNMT3A, and ASXL1. While often asymptomatic, CHIP has been linked to an increased risk of haematological malignancies and, crucially, to chronic inflammatory conditions, atherosclerosis, and cardiovascular disease. The prevailing hypothesis for these associations involves the production of pro-inflammatory cytokines by CHIP-mutated myeloid cells, creating a systemic inflammatory state. However, its direct influence on solid tumour progression remained an open question.
Unveiling the Tumour’s Hidden Invaders: TI-CH
The initial examination of blood samples from the TRACERx and PEACE lung cancer cohorts revealed that the presence of CHIP mutations was significantly correlated with a shorter overall survival for patients. This critical observation held true even after rigorous statistical adjustments for confounding factors such as the patient’s age at diagnosis, their smoking history, and the stage and grade of the cancer. This suggested that CHIP was an independent prognostic factor, not merely a proxy for advanced age or disease severity.
The pivotal distinction came with the identification of Tumour Infiltrating Clonal Haematopoiesis (TI-CH). Researchers went beyond simply detecting CHIP in the blood, painstakingly analyzing tumour tissue itself. They found that in 42% of patients with CHIP, the same mutations detected in their blood were also present within the lung tumours. This infiltration was not random; it marked a significant shift in prognosis. The data unequivocally showed that TI-CH, rather than CHIP in the blood alone, was the driving factor behind the heightened risk of cancer relapse and overall cancer-related mortality. This suggests an active role of these mutant blood cells within the tumour microenvironment, directly contributing to its aggressive behaviour.
Further compelling evidence emerged from the PEACE study, a unique post-mortem investigation that provides unparalleled access to metastatic sites – the areas where cancer has spread and the ultimate cause of death for most cancer patients. The finding that metastatic tumours at these sites frequently harboured TI-CH mutations provided strong support for the hypothesis that these infiltrating blood cells play a role in the most lethal aspects of cancer progression and dissemination.
The Role of Myeloid Cells and the TET2 Mutation
To understand how TI-CH exerts its detrimental effects, the researchers delved into the cellular composition of the tumour microenvironment. They observed that patients with TI-CH exhibited a marked expansion of myeloid cells within their lung tumours. Myeloid cells are a diverse group of immune cells, including macrophages, neutrophils, and dendritic cells, which are integral components of the tumour microenvironment. While some immune cells are renowned for their anti-tumour activity, myeloid cells often adopt pro-tumour functions. They can foster chronic inflammation, suppress adaptive anti-tumour immunity, promote angiogenesis (new blood vessel formation), and even directly support cancer cell proliferation and metastasis. The expansion of these cells, therefore, suggested a mechanism by which TI-CH could exacerbate tumour growth.
The investigation then narrowed down to specific genetic drivers. Among the various CHIP-associated mutations, those affecting the TET2 gene stood out. TET2 is a crucial epigenetic regulator, playing a vital role in DNA methylation and thus in normal blood cell production. The study revealed that TET2 mutant blood cells were significantly more likely to infiltrate tumours compared to other CHIP-mutated cells. To confirm the cellular localization of these mutations, the team performed single-cell RNA sequencing on hundreds of individual cells isolated from the tumours of two patients with TI-CH. This high-resolution analysis definitively showed that TET2 mutations were predominantly present in myeloid cells, specifically macrophages and monocytes, rather than in other immune cell types like T cells or B cells. This pinpointed TET2-mutated myeloid cells as key orchestrators of the pro-tumour effects.
To validate this causational link experimentally, the researchers collaborated with experts in blood cancer and CHIP biology. They developed innovative organoid models, essentially "mini lung tumours" grown in a dish. When these tumour organoids were co-cultured with TET2 mutant myeloid cells, the results were striking. The TET2 mutant myeloid cells actively remodelled the surrounding tumour microenvironment, creating conditions conducive to growth, and significantly accelerated the growth of the tumour organoids. This direct experimental evidence confirmed that TET2 mutant myeloid cells are not merely bystanders but active drivers of tumour progression.
Broader Implications Across Cancer Types
The generalizability of these findings was a critical next step. The collaboration with Memorial Sloan Kettering Cancer Center provided an unprecedented opportunity to validate the results across a vast and diverse patient population. Analyzing data from over 49,000 patients with various types of cancer, the team confirmed that the presence of TI-CH was indeed an independent predictor of shorter survival, consistent across numerous malignancies.
While the overall trend was clear, the prevalence and impact of CHIP and TI-CH varied between different cancer types. Researchers observed that these mutations were more common and had a particularly pronounced negative impact in cancers known for their aggressive nature and resistance to treatment, such as lung cancer (the focus of the initial study), head and neck cancer, and pancreatic cancer. This suggests that the interplay between age-related mutant blood cells and cancer progression might be particularly potent in malignancies that already present significant clinical challenges, potentially explaining some of their inherent recalcitrance to therapy. This extensive validation solidifies TI-CH as a broadly relevant prognostic factor and a novel target for therapeutic strategies in oncology.
Official Responses: Perspectives from the Forefront of Research
The publication of these findings has been met with significant enthusiasm from the scientific community, particularly from the lead researchers who have dedicated years to this complex investigation. Their insights underscore both the immediate impact and the long-term potential of this discovery.
Dr. Oriol Pich, a Postdoctoral Project Research Scientist in the Crick’s Cancer Evolution and Genome Instability Laboratory and a lead author of the study, emphasized the novelty and significance of the findings. "Our results show that blood cells carrying age-related mutations can infiltrate tumours and impact cancer evolution, leading to worse outcomes for patients," Dr. Pich stated. His comments highlight the paradigm shift this research introduces, moving beyond solely focusing on mutations within the cancer cells themselves to consider systemic factors originating from the ageing body. He further stressed the practical relevance, noting, "This is important because CHIP is a natural phenomenon of ageing that is common in patients with cancer." This ubiquity means that TI-CH could be a widespread, yet previously underappreciated, contributor to cancer aggressiveness, affecting a large proportion of the cancer patient population.
Professor Charlie Swanton, Deputy Clinical Director at the Crick, Chief Clinician at Cancer Research UK, and Chief Investigator for TRACERx, offered a broader perspective on the interaction between different biological processes. "This is the first time that we’ve been able to see at scale, the interaction of two different types of ‘clonal proliferations’, age-related CHIP and cancer, providing insight into how ageing might impact cancer risk," Professor Swanton explained. His statement refers to the simultaneous clonal expansion of both ageing blood cells (CHIP) and cancerous cells, revealing a complex, detrimental synergy. He articulated the profound implications for future interventions: "As we start to piece together the picture of the most important mutations which evolve during the ageing process in cells from the bone marrow, and the impact they have in disease, we hope we can start to identify opportunities for intervention and maybe even prevention of some age-related cancers." This forward-looking vision positions the research as a foundational step towards identifying novel therapeutic targets and potentially even preventative strategies that could mitigate the impact of ageing on cancer development and progression. The optimism is palpable, suggesting a future where understanding the nuances of ageing could unlock new frontiers in cancer care.
Implications: Reshaping Cancer Prognosis and Therapy
The discovery of Tumour Infiltrating Clonal Haematopoiesis (TI-CH) represents a profound step forward in our understanding of cancer biology, with far-reaching implications for clinical practice, future research, and ultimately, patient outcomes.
A Paradigm Shift in Understanding Cancer
This research fundamentally broadens our perspective on cancer progression. Historically, cancer research has predominantly focused on the genetic mutations and cellular mechanisms within the tumour cells themselves. While undeniably crucial, this study demonstrates that systemic, age-related changes occurring in seemingly healthy tissues – specifically, the blood-forming system – can profoundly influence the trajectory of cancer. It underscores the critical importance of the "tumour microenvironment" as a dynamic ecosystem, revealing a new, previously overlooked component: the infiltrating, age-mutated blood cells. This paradigm shift encourages a more holistic view of cancer, acknowledging it not just as a localized disease, but as a complex interplay between tumour-intrinsic factors and systemic host factors, particularly those linked to ageing.
Future Research Directions
The immediate next steps for this work are clearly defined: confirming that CHIP directly contributes to adverse cancer outcomes and detailing the exact mechanisms by which CHIP is functionally implicated in the development of aggressive cancers. This will likely involve:
- Longitudinal Studies: Following larger cohorts of CHIP patients over time to track cancer incidence, progression, and response to therapy, further solidifying the causal link.
- Deeper Molecular Profiling: Comprehensive multi-omics analyses (genomics, transcriptomics, proteomics, metabolomics) of TI-CH cells and the surrounding tumour microenvironment to identify novel signalling pathways and molecular targets.
- Advanced Preclinical Models: Development of more sophisticated in vitro and in vivo models that accurately mimic human TI-CH and its interaction with various cancer types, allowing for precise mechanistic dissection and drug screening.
- Investigation of Other CHIP Genes: While TET2 was a focus, further research is needed to understand if other CHIP-driving mutations (e.g., DNMT3A, ASXL1) also lead to tumour infiltration and similar pro-tumour effects.
- Interaction with Therapy: Exploring how TI-CH influences response to existing cancer therapies (chemotherapy, radiotherapy, immunotherapy) and identifying resistance mechanisms.
Potential for Clinical Impact
The clinical implications of this discovery are substantial and could manifest in several key areas:
- Enhanced Prognostic Assessment: Screening for TI-CH mutations, potentially through liquid biopsies or tumour tissue analysis, could serve as a powerful new biomarker to identify cancer patients at higher risk of relapse and mortality. This would allow for more personalized treatment stratification, where high-risk patients might receive more aggressive initial therapies or be prioritized for novel treatments.
- Novel Therapeutic Targets: The identification of TET2 mutant myeloid cells as active drivers of tumour growth opens exciting new avenues for drug development. Strategies could include:
- Targeting TET2-mutant cells: Developing therapies that specifically deplete or inhibit the pro-tumour functions of these infiltrating myeloid cells, without harming healthy immune cells.
- Modulating the Myeloid Microenvironment: Drugs that alter the inflammatory profile or suppress the pro-tumour activity of myeloid cells could be repurposed or developed.
- Epigenetic Therapies: Given TET2‘s role in epigenetics, existing or new epigenetic drugs might be explored for their ability to normalize TET2-mutant cell behaviour.
- Prevention Strategies: As Professor Swanton alluded, understanding the mechanisms by which age-related CHIP impacts cancer could pave the way for preventative interventions. If CHIP-driven inflammation is a key factor, strategies to mitigate chronic inflammation in individuals with CHIP could potentially reduce their risk of developing aggressive cancers. This could involve lifestyle modifications, anti-inflammatory agents, or other preventative measures.
The Broader Context of Ageing and Disease
This research powerfully reinforces the growing understanding that ageing is not merely a passive accumulation of damage but an active biological process with profound implications for health and disease. By linking age-related genetic changes in blood cells to cancer outcomes, the study underscores the importance of investigating the "biological interface of age-related genetic changes and diseases of ageing." As the global population ages, understanding and mitigating the health consequences of ageing, including cancer and cardiovascular disease, becomes paramount for public health. This discovery provides a crucial piece of the puzzle, emphasizing that ageing influences disease not just through cellular senescence or telomere shortening, but also through the clonal evolution of seemingly benign somatic mutations in distant tissues.
Funding and Collaborative Science
This monumental work would not have been possible without sustained funding and extensive international collaboration. The support from Cancer Research UK, the National Institute of Health and Care Research UCLH Biomedical Research Centre, alongside additional funders, highlights the essential role of research investment. The collaborative spirit demonstrated by institutions like the Francis Crick Institute, UCL, Gustave Roussy, and Memorial Sloan Kettering Cancer Center underscores that the most complex and impactful scientific questions often require the pooling of diverse expertise, resources, and patient cohorts from across the globe.
In conclusion, the discovery of TI-CH marks a pivotal moment in cancer research. By illuminating the previously hidden influence of age-related mutant blood cells on tumour progression, it offers a fresh perspective on cancer’s complexity and opens promising new avenues for improving diagnosis, prognosis, and therapeutic strategies for countless patients worldwide.
About the Author
